Romanian Society of Anesthesia and Intensive Care
Timișoara, Romania
NCT Number: NCT03265704
Maternal high blood pressure remodels the intrauterine environment of the fetus by altering hormonal and cellular signaling patterns and, as a result increases the risk of fetal and neonatal mortality and morbidity. Newborns of these mothers have an increased risk of intrauterine growth restriction, premature birth and hematological abnormalities, such as thrombocytopenia, polycythemia, and neutropenia. The purpose of the article is to review neonatal thrombocytopenia and neutropenia as a consequence of maternal high blood pressure and to establish the optimal management of these cases.
Looking for future studies?
Notify Me1 day–28 day
All sexes
Observational
Timișoara, Romania
Pregnancy induced hypertension (PIH) and preeclampsia (preE) are caused by gestation and have an onset after 20 weeks of pregnancy. Although the exact etiology of PIH and preE remains unknown, two interconnected mechanisms have been identified to play an important role in the pathogenesis: dysfunction of the placental trophoblast and endothelial dysfunction within the maternal systemic vasculature. The endothelium has been identified as the target tissue of the disease. Endothelial alterations ultimately manifest as placental hypoxia and hypoplasia. The neonatal thrombocytopenia and neutropenia after pregnancy-induced hypertension is a result of inhibition of fetal bone marrow production of the myeloid lineage due to intrauterine hypoxic environment. This study aims to investigate the hematological profile in term and preterm infants born to mothers with preeclampsia. The current retrospective observational study was conducted at the Clinic of Obstetrics, Gynecology and Neonatology of the Emergency County Hospital, Timisoara over a period of three years, from January 2014 to December 2016. All inborn patient files were analyzed as anonymised limited data sets from archived records of the Neonatology Department.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Data processing from Patient Medical Files
Data processing from Patient Medical Files
Monitoring PIH-related changes in the newborn
Monitoring PIH-related changes in the newborn
Time frame: Blood profiles of newborns aged between 1-28 days were evaluated.
Evaluating the impact of Maternal Pregnancy Induced Hypertension on fetal and neonatal hematopoiesis with focus on the myeloid lineage.
Romanian Society of Anesthesia and Intensive Care
Other
Maternal Pregnancy Induced Hypertension and Hematological Profile of Newborns
Acronym: MPIHHPN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01698957
Maternal-Fetal Exchange
Glendale, Arizona, United States
View Trial DetailsNCT05345561
Blood Platelet Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Chandler, Arizona, United States
View Trial DetailsNCT06043050
Blood Platelet Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Berlin, Metropolregion Berlin-Brandenburg, Germany
View Trial DetailsNCT04067375
Blood Platelet Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Amsterdam, Netherlands
View Trial Details